Research article · 26 Jul 2016
Conference abstractPublished 1 Oct 2012
Significance of BCR-ABL mutations, atypical FISH signal patterns and gene amplifications in imatinib resistance - A South Indian study
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
C hronic myeloid leukemia (CML) is a hematopoietic stem cell disorder characterized by the BCR-ABL oncogenic fusion gene. Treatment for patients with CML has been greatly improved by the use of imatinib, selective inhibitor of ABL kinase. However, most patients in advanced phase either exhibit primary refractoriness or relapse after an initial response to imatinib. The study was designed to find the major influencing cause of imatinib resistance in south Indian cohort. For this, a total of 182 CML suspects were recruited in the study. The chromosomal abnormalities observed in these cases were validated.Presence of Ph chromosome, being the most common observation apart from various common additional chromosomal abnormalities like trisomy8, double Ph, monosomy Y, ploidy changes etc and with few rare and significant chromosomal alterations with impact on leukemogenesis. The diagnostic confirmation was done using molecular cytogenetics(FISH) and/ or RT-PCR .Several cases showed derivative (9)deletions, which re-directed us to compare and analyze various parameters like hematological ,cytogenetic ,drug dose etc in these cases against controls. The hematological, cytogenetic and follow-up analysis (by FISH) showed some exclusive trends in cases showing der(9) deletions. The next objective was to role of gene amplification and / or BCR-ABL kinase domain mutations( (like T315I, F317L and G250E) in resistance. Out of the 35 resistance subjects delineated, the analysis was done on 23 patients (17M:6F). The gene amplification was not frequent, when status checked on 16 /23 resistance suspects, but instead showed FISH patterns like OGGF, OOGF, OGF. On 19/23 cases, ASO-PCR was done to detect three major mutations (T315I ,F317L,G250E) . Mutations T315I (11/19) and F317L (17/19) were common compared to G250E. In one patient, the F317L mutation transcript was atypical. For these cases, the clinical, hematological, socio-demographic parameters were also analyzed. The study is a torchbearer for future investigations on various common and rare observations in CML suspects. Also, on basal screening of resistance suspects, drug resistance is found least associated to gene amplification than mutations.
Subjects
BiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Commentary · 26 Apr 2021
Mutated forms of BCR-ABL gene
Research article · 2018
The Potential Inhibitors in Traditional Chinese Medicine for BCR-ABL T315I Mutation of Chronic Myelogenous Leukemia
Short communication · 2016
Tyrosine Kinase Inhibitors and Phosphatases: Overcoming the BCR-ABL T315I Mutation in CML with a Synergistic Combination of Ponatinib and Forskolin
Conference abstract
Retrospective analysis of allele specific oligonucleotideâ??polymerase chain reaction (ASO-PCR), as method for detection of three BCR-ABL kinase domain mutations (T315I, M351T and F311L) in chronic myelogenous leukemi
More from this journal
The newest in Journal of Cell Science & Therapy.
Perspective · 2 Feb 2026
Exploring Senescence and Its Influence on Tissue Function and Therapeutic Research
Commentary · 2 Feb 2026
Metabolism Regulation and Its Influence on Therapeutic Development in Human Disease
Commentary · 2 Dec 2025
Cellular Membranes and Transport Proteins as Regulators of Homeostasis and Metabolic Coordination
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Cell Science & Therapy
- SubjectBiology
- BylineArticles whose byline prints “Sangeetha Vijay”

